Melanoma antibody

Catalog No. ABIN6252231

This Mouse Monoclonal antibody specifically detects Melanoma in IHC (p), IF and WB. It exhibits reactivity toward Human, Dog and Mouse.

Quick Overview for Melanoma antibody (ABIN6252231)

Target: Melanoma

Reactivity: Human, Dog, Mouse

Host: Mouse

Clonality: Monoclonal

Conjugate: This Melanoma antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunofluorescence (IF), Western Blotting (WB)

Clone: PNL2

Product Details anti-Melanoma Antibody

Purification: Protein G affinity chromatography

Immunogen: Melanocyte antigen was used as the immunogen for the Melanoma antibody PNL2.

Isotype: IgG1

Application Details

Application Notes: Immunofluorescence: 0.5-1 μg/mL

Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)

Prediluted format: incubate for 30 min at RT (2)

Optimal dilution of the Melanoma antibody PNL2 should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Citrate buffer,  pH 6.0, for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: PBS with 0.1 mg/mL BSA and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot and Store at -20C. Avoid freez-thaw cycles.

Target Details for Melanoma

Target: Melanoma

Background: Anti-PNL2 is a novel monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope id not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87 % ), as opposed to 76 % for anti-HMB45 and 82 % for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angio-myolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.